Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On October 14, 2024, Champions Oncology, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows:
1. Election of Directors.The seven director nominees named in the Company's 2024 proxy statement were elected to serve for a one-year term expiring at the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes:
|
Director Nominee
|
Votes For
|
Votes Withheld
|
Broker Non-Vote
|
Ronnie Morris, M.D.
|
8,483,091
|
685,123
|
697,813
|
Joel Ackerman
|
7,973,309
|
1,194,905
|
697,813
|
David Sidransky, M.D.
|
7,997,992
|
1,170,222
|
697,813
|
Daniel Mendelson
|
7,769,799
|
1,398,415
|
697,813
|
Scott R. Tobin
|
9,167,706
|
508
|
697,813
|
Philip Breitfeld, MD.
|
9,167,215
|
999
|
697,813
|
Robert Brainin
|
7,888,299
|
1,279,915
|
697,813
|
2. Ratification of Appointment of Independent Registered Accounting Firm.The appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2025, was ratified as follows:
|
Votes For
|
Votes Against
|
Abstain
|
9,865,571
|
256
|
200
|
3. Non-binding Advisory Resolution Relating to the Compensation of the Company's Named Executive Officers.The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2024 proxy statement, was approved by the following votes:
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Vote
|
9,162,287
|
2,027
|
3,900
|
697,813
|